NVO - Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
2024-06-08 09:00:00 ET
Odds are that if you hear the word "Ozempic," you likely associate that with weight loss. It's hard not to given all the posts on social media about users losing weight thanks to the drug. But many people may be surprised that it's not actually approved as a weight loss treatment -- regulators have approved it for diabetes. People have simply been taking it off-label because of its ability to help them lose weight.
But that's a great example of how diverse and wide-ranging the benefits may be from not just Ozempic but other, similar glucagon-like peptide 1 (GLP-1) treatments as well. Novo Nordisk (NYSE: NVO) makes Ozempic and has another GLP-1 drug, Wegovy, which is actually approved for weight loss.
As strong as sales for these products have been of late, they could go even higher in the future.
For further details see:
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher